Braveheart Bio, Inc.
Braveheart Bio is a clinical-stage biopharmaceutical company based in San Francisco, California. It develops therapies for people with hypertrophic cardiomyopathy and other serious cardiovascular conditions. Its drug candidates, BHB-1893 and HRS-1893, are oral small-molecule cardiac myosin inhibitors intended to treat obstructive and non-obstructive hypertrophic cardiomyopathy.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BRVE in the last 30 days.
See all $BRVE insider activity →Jiangsu Hengrui Pharmaceuticals (1276.HK) and Braveheart Bio (BRVE) reported positive 52-week data for HRS/BHB-1893 in oHCM patients, showing improved exercise capacity and quality of life. The drug was well-tolerated, with no serious adverse events. Braveheart plans a Phase 2b study. 1276.HK closed at HKD 50.950, BRVE at $18.60.
Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Regulation FD Disclosure. Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capaci
Braveheart Bio (BRVE) and Hengrui Pharma (SSE: 600276, HKEX: 1276) presented 52-week data on HRS/BHB-1893, showing improved exercise capacity and patient outcomes in oHCM patients. The drug demonstrated rapid, durable LVOT gradient reduction and potential diastolic function improvements. Braveheart Bio will host an investor event to discuss the data and future plans, including a planned Phase 2b study.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning BRVE (Braveheart Bio, Inc.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 0 bearish.
Recent BRVE coverage spans financial news, technology and earnings.
The data and upcoming Phase 2b trial may attract additional funding and raise the stock.
Positive Phase 2 extension data should lift sentiment and may trigger a short‑term price rally.
Positive Phase 2 extension data likely lifts sentiment on Braveheart Bio.
The upcoming data could validate long‑term efficacy and safety, potentially boosting the stock.
Analyst upgrades suggest upside potential for BRVE.
AlphAI scores every news story that mentions BRVE with an AI model for sentiment and relevance, and aggregates insider trades from Braveheart Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jiangsu Hengrui Pharmaceuticals (1276.HK) and Braveheart Bio (BRVE) reported positive 52-week data for HRS/BHB-1893 in oHCM patients, showing improved exercise capacity and quality of life. The drug was well-tolerated, with no serious adverse events. Braveheart plans a Phase 2b study. 1276.HK closed at HKD 50.950, BRVE at $18.60.
Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Regulation FD Disclosure. Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capaci
Braveheart Bio (BRVE) and Hengrui Pharma (SSE: 600276, HKEX: 1276) presented 52-week data on HRS/BHB-1893, showing improved exercise capacity and patient outcomes in oHCM patients. The drug demonstrated rapid, durable LVOT gradient reduction and potential diastolic function improvements. Braveheart Bio will host an investor event to discuss the data and future plans, including a planned Phase 2b study.
Braveheart Bio (BRVE) will present 52-week data on BHB-1893 for hypertrophic cardiomyopathy at AHA Scientific Sessions 2026. Presentations include long-term efficacy and safety results, and in vitro study evidence. Materials will be available on the company's website post-presentation.
Stifel maintained a Buy rating and $45 target on Braveheart Bio (BRVE) after the company presented at its Virtual Cardiometabolic Forum. BRVE's stock is down 13.6% over the past week, trading near its 52-week low. Management expressed confidence in BHB-1893, their drug candidate for hypertrophic cardiomyopathy. Upcoming catalysts include phase 2 and phase 3 trial data. Multiple analysts have recently rated BRVE positively, with targets ranging from $40 to $48.
Braveheart Bio Inc. shares rose 5.50% to $29.24 after initiating a Phase 3 trial for its heart drug BHB-1893. The company reported Q2 2026 financials, with R&D expenses at $11.1M and a net loss of $18.6M. Analysts have a Strong Buy consensus with an average price target of $45.25.
Goldman Sachs reiterated a buy rating on Braveheart Bio (BRVE) with a $48 price target, suggesting 80% upside from its current price. The biotech firm has a Strong Buy consensus among analysts, with targets ranging from $40 to $48. Recent analyst reports highlight progress in key trials and promising data for BHB-1893, a cardiac myosin inhibitor.
Goldman Sachs recommends two under-the-radar IPO stocks: Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE). LTGO, which develops non-opioid pain relief drugs, raised $345.6M in its IPO and has a market cap of $1.5B. Goldman's analyst sets a $73 price target, implying a 217% gain. BRVE focuses on hypertrophic cardiomyopathy treatments and plans Phase 3 trials next year. Both stocks have unanimous 'Buy' ratings from analysts.
Braveheart Bio Inc (BRVE) filed its Q2 2026 10-Q, showing a GF Score of 8/100, reflecting financial challenges but potential growth. The company's flagship product, BHB-1893, targets hypertrophic cardiomyopathy (HCM). BRVE raised $439.9M in its IPO and faces risks from financial instability and reliance on a single product.
Braveheart Bio (Nasdaq: BRVE) completed its IPO, raising $122.8 million. The proceeds will fund its lead drug candidate, BHB-1893, for hypertrophic cardiomyopathy. The company reported Q2 2026 R&D expenses of $11.1 million and a net loss of $18.6 million. Cash reserves increased to $122.8 million as of June 30, 2026.
